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Abstract 
 
Purpose. To evaluate the association between Wilms tumor histology at diagnosis and the 
change in Wilms’ tumor volume during preoperative chemotherapy. 
Methods. We included all the 52 patients operated for Wilms tumor at 1988-2015, who had 
both pathology samples and either CT or MRI-images before and after preoperative 
chemotherapy, available for re-evaluation. 
Results: The median tumor volume was 586ml (IQR 323-903) at diagnosis. The median 
change in tumor volume was -68% (IQR -85—40, p<0.001) and the proportion of tumor 
necrosis 85% (IQR 24-97), after preoperative chemotherapy. There was a correlation between 
blastemal cell content in pre-chemotherapy needle biopsy sample and the reduction in tumor 
volume (Rho=-0.452, p=0.002). High stromal and epithelial cell contents in CNB samples 
were associated with the lesser change in tumor volume (Rho=0.279, p=0.006 and 
Rho=0.300, p=0.038 respectively). Reduction of tumor volume and the proportion of tumor 
necrosis after chemotherapy were associated (Rho=- 0.502, p<0.001). The actual viable tumor 
volume decreased in median by 97% (IQR 65-100), and the decrease could be seen in all 
cellular components. In three patients, the tumor volume increased more than 10% during the 
preoperative chemotherapy. Two of them had anaplastic tumor in the nephrectomy specimen. 
Conclusion: Wilms tumor total and viable tumor volumes reduced by 68% and 97% with 
preoperative chemotherapy, respectively. High proportion of blastemal cells in CNB was 
associated with greatest decrease in Wilms tumor volume. Increase in tumor volume during 
preoperative chemotherapy may indicate anaplastic tumor and prolonging of preoperative 
therapy should be avoided. 
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Type of study: Retrospective review 
 
Level of evidence: Level III 
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Effect of Wilms tumor histology on response to neoadjuvant chemotherapy 
 
Wilms tumor is often large and fragile. Consequently, large tumors are prone to rupture 
during surgery [1,2]. Preoperative chemotherapy is systematically used in The International 
Society of Pediatric Oncology (SIOP) and United Kingdom Children’s Cancer Study Group 
(UKCCSG) treatment protocols and, in the case of inoperable tumors, by others too[3-5]. 
Following preoperative chemotherapy, the tumor size often shrinks enabling a safer 
operation with a decreased risk for tumor rupture [6]. In addition, the down-staging of the 
tumor with preoperative chemotherapy has been suggested to spare 20% of the patients from 
radiotherapy or doxorubicin by UKW-3 study [7].
 
In a previous SIOP-9 study, tumors with 
stromal or epithelial predominance after chemotherapy had reduced less in volume than the 
tumors with necrotic, regressive or blastemal predominance [8].
 
However, association 
between pre-chemotherapy histology and tumor volume change during chemotherapy has not 
been investigated in detail previously.  
To confirm diagnosis and to direct the most appropriate neoadjuvant regimen according 
to histology, cutting needle biopsy (CNB) has been used at diagnosis in our center as well as 
in some other centers [9-12]. This allows us to compare the histological findings of the 
primary biopsy to the tumor volume changes during the preoperative chemotherapy, which is 
the primary goal of our study. In addition, we evaluated the association between 
postchemotherapy findings and the effect of the length of preoperative chemotherapy to the 
tumor volume change. Our hypothesis is that prechemotherapy histology has impact on 
the tumor response. 
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1. Methods 
1.1 Data source and subjects 
The study cohort was identified by a retrospective review of the surgical database for patients 
operated for renal tumors in 1988 through 2015 in the Children´s Hospital, University of 
Helsinki. The institutional ethics committee had approved the study. Altogether 90 patients 
were operated because of renal tumor and 70 of them had had diagnostic CNB. 
 
Diagnostic CNB has been part of our clinical work up of renal tumors since the initial 
report . [9] CNB was not performed in case of  small, by imaging intrarenal tumors, 
cystic tumors and tumors with active bleeding. . CNB was taken by using ultrasound 
guidance from the back or flank to avoid peritoneum, and at least two acceptable-
quality cylinders were collected. Originally, manual core needles were used but during 
the last 20 years automatic cutting needles (at present BioPince® 18ga, Argon Medical 
Devices, Tx, USA) have been used. 
 
We excluded six patients whose pathology slides could not be found for re-evaluation 
and five patients with a non-Wilms tumor. An additional seven patients were excluded 
due to lacking either pre- or postchemotherapy CT- or MRI-images.    Accordingly, we 
included to the final analysis all the 52 Wilms tumor patients who had both original 
preoperative CNB and the histological samples from nephrectomy available as well as CT- or 
MRI-images from both before and after chemotherapy. The pathology slides were re-
evaluated by an experienced pathologist (JL) to confirm the diagnosis and to classify the 
response to preoperative chemotherapy according to current guidelines [13]. The structured 
histological evaluation included the estimation of the degree of necrosis (necrotic= 100% 
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necrosis, regressive= 66-99% necrosis, poor response= necrosis <66%), proportions of the 
cellular components of Wilms tumor (epithelial, blastemal, stromal) were expressed as a 
percent of the total surface area of the viable tissue of the tumor, and the presence of 
anaplasia (focal or diffuse) [13]. Operative staging of the tumors was done by SIOP WT 
2001 staging criteria [13]. Images were re-evaluated by a radiologist (OL) for the exact 
tumor volumes with ellipsoid formula (0.523 x a x b x c) [14]. 
 
Viable tumor volume in 
nephrectomy specimen was calculated by reducing the proportion of necrotic tumor 
(determined from histologic sample) from actual tumor volume in imaging study. At 
diagnosis the whole tumor was considered to be viable. 
2.2 Chemotherapy regimen 
The chemotherapy regimen used preoperatively was based on dactinomycin and vincristine 
for 2 weeks -3 months intensified with alkylators or anthracycline in patients with metastases 
or biopsy showing either anaplasia or in the early series if the histology was composed mostly 
of blastemal cells.[15] The length of chemotherapy was often increased from the standard one 
month if the reduction of tumor volume was considered insufficient, especially in the early 
series. 
 
2.3 Statistical analysis 
The association between different cellular components on CNB and the degree of necrosis or 
reduction in tumor volume was evaluated with Spearman correlation. The change in tumor 
volume was evaluated with Wilcoxon signed rank test. Continuous variables are expressed as 
medians and interquartile ranges (IQR) or ranges. For the analyses Statview
® 
5.0.1, SAS 
Institute Inc. was used. P-value <0.05 was considered significant.  
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2. Results 
2.1. Patient characteristics 
Twenty-three of the 52 patients were male. The median age at diagnosis was 3.4 years (IQR 
2.0-5.0). The tumor was located on the right or left side, or bilateral in 28 (54%), 21 (40%) 
and three (6%) patients, respectively.  In the cases of bilateral tumor, only the larger tumor 
was evaluated.  
2.2. Histology of the specimens 
The proportion of blastemal, stromal and epithelial components in the diagnostic CNB were 
60% (IQR 25-86), 20% (IQR 0-50) and 2% (IQR 0-10), respectively. The proportion of 
necrosis was 85% (IQR 24-97) in the nephrectomy samples. The nephrectomy specimens 
were classified as fully necrotic and regressive in 5 (10%) and 23 (44%) cases, respectively. 
The tumors with necrosis less than 66% were mixed in 8 (15%), blastemal type in l4 
(8%), stromal type in 8 (15%) and epithelial type in 2 (4%). Two cases (4%) were 
nephrobastomas with diffuse anaplasia. Operative local stage 1 was confirmed  in 30, 
stagem2 in nine and stage 3 in 13 cases. 
2.3. Change in tumor volume 
The median tumor volume at diagnosis was 583 ml (IQR 368-903) and the greatest dimension 
was 127 mm (IQR 99-144). The median volume change during the preoperative 
chemotherapy was -68% (IQR-85- -40, range -98- +265, p<0.001).  The more the tumor 
volume reduced during the preoperative chemotherapy, the larger the tumor necrosis was in 
the nephrectomy specimen (Rho=-0.502, p<0.001, Fig. 1). In two cases, tumor volume did 
not decrease despite of complete or near complete tumor necrosis. In three patients, the 
tumor volume increased more than 10% during the preoperative chemotherapy (Fig. 2). Two 
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of them had anaplastic tumor (increase in tumor volume 26 and 265%) and the third showed 
stromal predominance in the nephrectomy specimen (volume increase 34%).  
 
The proportion of blastemal component in CNB  correlated with the reduction in tumor 
volume during the preoperative chemotherapy (p=0.002, Fig. 3). Accordingly, the higher the 
content of stromal or epithelial component in the CNB, the less was the reduction in tumor 
volume (p=0.053 and p=0.038 respectively).  
 
When the degree of tumor necrosis and the change in tumor volume were combined the actual 
decrease in viable tumor volume was in median 97% (IQR 65-100) and the reduction could be 
seen in all cellular components (99% (IQR 93-100) in blastemal, 98% (IQR 55-100) in 
stromal and 85% (IQR 27-99) in epithelial component). In nine patients treated with 2-3-
months’ preoperative chemotherapy, CT or MRI images were available also after 4-6-weeks’ 
chemotherapy. In six of them tumor shrank more than 10%, the tumor size remained 
unchanged in one patient and in two patients (one with anaplastic tumor and the other with 
stromal type tumor) the tumor grew with prolonged chemotherapy. 
 
3. Discussion 
The median reduction in Wilms tumor volume was 68% with pre-operative chemotherapy. A 
high proportion of blastemal cells in diagnostic CNB was associated with a significant 
decrease in Wilms tumor volume, whereas high percentage of stromal or epithelial cells was 
associated with poor reduction in tumor volume during the pre-operative chemotherapy. 
However, the actual viable volume of all these three components decreased during the 
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chemotherapy. Tumor growth was rare during the pre-operative chemotherapy and it was 
associated with diffuse anaplasia in two of the three cases.  
In previous studies evaluating the effect of preoperative chemotherapy on tumor volume no 
comparisons were made to prechemotherapy histology in contrast to our study. In SIOP-9 
study with 1052 patients, the median tumor volume reduction was 62% with preoperative 
chemotherapy [16]. An increase in tumor volume was observed in 12% of the patients.  In 
SIOP-9 /GPOH study, analyzing the association between tumor histology in nephrectomy 
samples and the change in tumor volume during preoperative chemotherapy, more than 40% 
of decrease in volume was common in necrotic, regressive, mixed or blastemal type tumor in 
nephrectomy specimens but rare in epithelial and stromal type tumors [8]. Our results are in 
accordance with those results. In a cohort of patients treated in UKW-3 study, all five high 
risk tumors reduced in tumor volume (in median by 79%). However, among patients 
belonging to intermediate risk group (epithelial, stromal, regressive or focal anaplasia type in 
nephrectomy specimen) only 10/15 had reduction in tumor volume whereas 5/15 had increase 
in tumor volume [17]. Similarly, in a study from Belgium, in which most tumors belonged to 
the intermediate group, the mean reduction of tumor volume was 61% in 12/17 cases, 
whereas in the remaining five cases tumor volume increased in mean by 43% [18]. When 
applying the UK study risk classification criteria to our study, six high risk tumors with 
blastemal predominance after chemotherapy had comparable decrease in tumor volume as in 
the UK study. However, in contrast to the UK study, both tumors with diffuse anaplasia in our 
series were chemoresistant and grew despite the use of preoperative chemotherapy. 
Furthermore, in our study only one (stromal type) of 42 intermediate risk tumors continued to 
grow despite of chemotherapy.  
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Our study has several limitations rising from the retrospective nature of this study. In 
addition, the calculation of viable tumor volume was based on assumption that before 
chemotherapy the whole tumor is viable, which is in many cases apparently not true. In 
post chemotherapy samples the degree of necrosis was based completely on 
histopathology evaluation. Accordingly, it is possible that in some cases the reported 
decrease in viable tumor is overestimated. However, all the histological samples were re-
evaluated by an experienced pathologist and all the imaging studies were evaluated by a 
radiologist to cover the possible inter-examiner bias of the histological findings and tumor 
volumes.  In addition, because this study analyses the results from the last 30 years, there 
have been changes in both chemotherapy and the length of preoperative therapy.  
 
4. Conclusions 
Primary chemotherapy before nephrectomy reduces the median total volume  68 percent 
and the viable Wilms tumor volume  97 percent. The tumors that do not shrink during the 
preoperative chemotherapy more often have a predominant epithelial or stromal component 
remaining. Tumor growth during chemotherapy may indicate anaplastic tumor and 
prolonging chemotherapy should be avoided. 
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Figure legends 
 
Fig. 1. Degree of necrosis and the change in tumor volume after pre-operative chemotherapy 
in 50 
patients with Wilms tumor. The patients with anaplastic tumors were excluded. 
 
Fig.2. Wilms tumor histological classification in 52 nephrectomy specimens and the change in 
tumor volume during preoperative chemotherapy. 
 
Fig. 3. The change in tumor volume during preoperative chemotherapy and the proportion of 
different cellular components in CNB at diagnosis. 
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